
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
"Tell me about these melon-collie feelings."
This article was originally posted on July 13, 2016, and has since been updated. -Ed




